TABLE 1.
Organism | No. of isolates | Compound | MIC range (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) |
---|---|---|---|---|---|
S. aureus | |||||
All | 191 | RWJ-416457 | 0.25-16 | 1 | 2 |
191 | Linezolid | 0.5->32 | 4 | 4 | |
181 | Vancomycin | 0.5-8 | 1 | 4 | |
Methicillin-susceptible | 72 | RWJ-416457 | 0.5-4 | 1 | 2 |
Linezolid | 2-4 | 2 | 4 | ||
Vancomycin | 1-2 | 1 | 2 | ||
Methicillin-resistant (hospital-associated MRSA, linezolid-susceptible)a | 102 | RWJ-416457 | 0.25-4 | 1 | 2 |
Linezolid | 0.5-4 | 4 | 4 | ||
Vancomycin | 0.5-8 | 1 | 4 | ||
Oxacillin | 4->32 | >32 | >32 | ||
Vancomycin-intermediate (MRSA)a | 13 | RWJ-416457 | 0.25-2 | 0.5 | 2 |
Linezolid | 0.5-4 | 1 | 4 | ||
Vancomycin | 2-8 | 4 | 8 | ||
Oxacillin | 4->32 | >32 | >32 | ||
Linezolid-resistant (MRSA)a | 4 | RWJ-416457 | 4-16 | NAb | NA |
Linezolid | 8->32 | NA | NA | ||
Vancomycin | 1-2 | NA | NA | ||
Oxacillin | >32 | NA | NA | ||
Community-acquired MRSA | 13 | RWJ-416457 | 1-2 | 1 | 2 |
Linezolid | 2-4 | 4 | 4 | ||
Vancomycin | 1 | 1 | 1 | ||
Oxacillin | 16-32 | 32 | 32 | ||
Coagulase-negative staphylococci | |||||
All | 67 | RWJ-416457 | 0.25-1 | 0.5 | 1 |
Linezolid | 0.5-2 | 2 | 2 | ||
Vancomycin | 0.5-4 | 2 | 4 | ||
Oxacillin | 0.12->16 | >16 | >16 | ||
Methicillin-susceptible | 14 | RWJ-416457 | 0.25-1 | 0.5 | 0.5 |
Linezolid | 1-2 | 1 | 2 | ||
Vancomycin | 1-4 | 2 | 4 | ||
Oxacillin | 0.12-0.25 | 0.12 | 0.25 | ||
Methicillin-resistant | 53 | RWJ-416457 | 0.25-1 | 0.5 | 1 |
Linezolid | 0.5-2 | 2 | 2 | ||
Vancomycin | 0.5-4 | 2 | 4 | ||
Oxacillin | 0.5->16 | >16 | >16 | ||
E. faecalis | |||||
Linezolid-susceptible | 42 | RWJ-416457 | 0.5-2 | 0.5 | 1 |
Linezolid | 1-4 | 2 | 2 | ||
Vancomycin | 1->16 | 4 | >16 | ||
Linezolid-resistant | 1 | RWJ-416457 | 32 | NA | NA |
Linezolid | 64 | NA | NA | ||
Vancomycin | >128 | NA | NA | ||
E. faecium | |||||
Linezolid-susceptible | 36 | RWJ-416457 | 0.25-1 | 1 | 1 |
Linezolid | 0.5-4 | 2 | 4 | ||
Vancomycin | 1->16 | >16 | >16 | ||
Linezolid-resistant | 2 | RWJ-416457 | 16 | NA | NA |
Linezolid | 32-64 | NA | NA | ||
Vancomycin | >128 | NA | NA | ||
Enterococcus gallinarum (linezolid-resistant) | 1 | RWJ-416457 | 16 | NA | NA |
Linezolid | 64 | NA | NA | ||
Vancomycin | >128 | NA | NA | ||
Streptococcus pyogenes (37 macrolide-resistant isolates) | 39 | RWJ-416457 | 0.25-0.5 | 0.5 | 0.5 |
Linezolid | 1-2 | 1 | 2 | ||
Erythromycin | 0.03->16 | 8 | >16 | ||
S. pneumoniae | 108 | RWJ-416457 | 0.06-1 | 0.5 | 0.5 |
All | Linezolid | 0.25-2 | 1 | 1 | |
Penicillin-resistant | 31 | RWJ-416457 | 0.25-1 | 0.5 | 0.5 |
Linezolid | 0.5-2 | 1 | 1 | ||
Penicillin | 2-4 | 2 | 4 | ||
Macrolide-resistant | 51 | RWJ-416457 | 0.25-1 | 0.5 | 0.5 |
Linezolid | 0.5-2 | 1 | 1 | ||
Erythromycin | 1->16 | 4 | >16 | ||
Fluoroquinolone-resistant | 20 | RWJ-416457 | 0.06-1 | 0.5 | 0.5 |
Linezolid | 0.5-2 | 0.5 | 1 | ||
Levofloxacin | 8->32 | 16 | >16 | ||
H. influenzae | 4 | RWJ-416457 | 8->16 | NA | NA |
Linezolid | 4-16 | NA | NA | ||
Erythromycin | 2-8 | NA | NA | ||
M. catarrhalis | 12 | RWJ-416457 | 2-4 | 2 | 4 |
Linezolid | 4-8 | 8 | 8 | ||
Erythromycin | 0.12-0.25 | 0.25 | 0.25 | ||
L. pneumophila | 17 | RWJ-416457 | 2-64 | 4 | 8 |
Linezolid | 1-64 | 4 | 16 | ||
Levofloxacin | 0.03-0.5 | 0.12 | 0.5 | ||
M. pneumoniae | 17 | RWJ-416457 | 16-32 | 16 | 32 |
Linezolid | 64->64 | >64 | >64 | ||
Levofloxacin | 0.5-1 | 0.5 | 1 | ||
C. pneumoniae | 3 | RWJ-416457 | 16-64 | NA | NA |
Linezolid | 64->64 | NA | NA | ||
Levofloxacin | 0.5 | NA | NA |
Isolates received through the Network on Antimicrobial Resistance in S. aureus (NARSA) program.
NA, not applicable.